CANbridge Life Sciences Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CANbridge Life Sciences Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11300
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Canbridge Life Sciences Ltd (Canbridge) is a biopharmaceutical company that offers development and commercialization of specialty healthcare products. The company’s pipeline products include CAN-008, an antibody-like CD95 receptor and Fc-fusion protein used to reduce cancer-cell migration in malignant glioma and protecting tumor-infiltrating immune cells from apoptosis; CAN-002, calcium phosphate oral rinse solution indicated for mucositis caused by high dose chemotherapy and CAN-017, a humanized immunoglobulin gamma 1 and kappa monoclonal antibody, that targets the human v-erb-b2 oncogene homolog 3 (ERBB3 or HER-3) receptor. It has partnership with other bio-pharmaceutical companies and academic institutions. CANbridge is headquartered in Beijing, China.

CANbridge Life Sciences Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CANbridge Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 9
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CANbridge Life Sciences Raises USD25 Million in Series B Financing 11
CANbridge Life Sciences Raises USD10 Million in Series A Venture Financing 12
Partnerships 13
CANbridge Pharma and WuXi Biologics Enter into Partnership 13
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 14
Licensing Agreements 15
CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 15
CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 16
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 18
Azaya Therapeutics Enters Into Licensing Agreement With Canbridge Life Sciences For ATI-1123 19
CANbridge Life Sciences Ltd – Key Competitors 21
CANbridge Life Sciences Ltd – Key Employees 22
CANbridge Life Sciences Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Corporate Communications 24
Jul 31, 2018: CANbridge Life Sciences Appoints Chief Medical Officer 24
Sep 12, 2017: CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CANbridge Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
CANbridge Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 9
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CANbridge Life Sciences Raises USD25 Million in Series B Financing 11
CANbridge Life Sciences Raises USD10 Million in Series A Venture Financing 12
CANbridge Pharma and WuXi Biologics Enter into Partnership 13
Canbridge Life Sciences Enters into Co-Marketing Agreement with Eusa Pharma for Caphosol 14
CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 15
CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 16
CANbridge Life Sciences Extends Licensing Agreement with Apogenix 18
Azaya Therapeutics Enters Into Licensing Agreement With Canbridge Life Sciences For ATI-1123 19
CANbridge Life Sciences Ltd, Key Competitors 21
CANbridge Life Sciences Ltd, Key Employees 22
CANbridge Life Sciences Ltd, Other Locations 23

List of Figures
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CANbridge Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CANbridge Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[CANbridge Life Sciences Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fresenius Kabi USA LLC:企業の戦略的SWOT分析
    Fresenius Kabi USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Smith & Nephew plc:企業のM&A・事業提携・投資動向
    Smith & Nephew plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Smith & Nephew plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Masterflex SE (MZX):企業の財務・戦略的SWOT分析
    Summary Masterflex SE (Masterflex), formerly Masterflex AG, is a manufacturer and supplier of spiral hoses. The company manufactures and markets high-tech spiral hoses. It offers hoses and connecting systems such as abrasion-resistant suction and transport hoses made from PU, suction and transport h …
  • Albireo Pharma Inc (ALBO):企業の財務・戦略的SWOT分析
    Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • NovaBay Pharmaceuticals Inc (NBY)-製薬・医療分野:企業M&A・提携分析
    Summary NovaBay Pharmaceuticals Inc (NovaBay), formerly NovaCal Pharmaceuticals Inc is a biopharmaceutical company that develops eyecare products. The company’s products include daily lid and lash hygiene spray solution, skin and wound cleanser, and cosetic procedures. Its daily lid and lash hygiene …
  • Sanofi SA:企業の戦略・SWOT・財務情報
    Sanofi SA - Strategy, SWOT and Corporate Finance Report Summary Sanofi SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Danieli & C. Officine Meccaniche SpA:企業の戦略・SWOT・財務情報
    Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report Summary Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Sharjah Electricity & Water Authority:企業の戦略的SWOT分析
    Sharjah Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Shibuya Kogyo Co., Ltd.:企業の戦略・SWOT・財務情報
    Shibuya Kogyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shibuya Kogyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Agilent Technologies Inc (A):企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hyundai Motor Co (005380):企業の財務・戦略的SWOT分析
    Hyundai Motor Co (005380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Qiagen Marseille SA-医療機器分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • WPPI Energy Inc:企業の戦略的SWOT分析
    WPPI Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Selvita SA (SLV):製薬・医療:M&Aディール及び事業提携情報
    Summary Selvita SA (Selvita) is a drug discovery company that focuses on the research and development of cancer therapies. The company develops novel small molecule drugs, and markets them with partners from the pharmaceutical industry. Its products find application in the therapeutic areas of oncol …
  • aap Implantate AG (AAQ):企業の製品パイプライン分析2018
    Summary aap Implantate AG (aap Implantate) is a medical device company, which develops, manufactures and markets trauma products and biomaterials for orthopedic treatment. Its products include locked plating systems for anatomical reduction, cannulated screws, standard plates and screws for osteosyn …
  • Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • American Builders & Contractors Supply Co Inc:企業の戦略・SWOT・財務情報
    American Builders & Contractors Supply Co Inc - Strategy, SWOT and Corporate Finance Report Summary American Builders & Contractors Supply Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • A.S. Watson Group (HK) Limited:企業の戦略・SWOT・財務情報
    A.S. Watson Group (HK) Limited - Strategy, SWOT and Corporate Finance Report Summary A.S. Watson Group (HK) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析
    Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • ABN AMRO Group NV (ABN):企業の財務・戦略的SWOT分析
    ABN AMRO Group NV (ABN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆